A major hedge-fund investor will meet top executives of CVS Health on Monday to propose ways the struggling healthcare company can improve its operations, the potential start of an activist stance by the fund, The Wall Street Journal’s Gregory Zuckerman and Anna Wilde Mathews report, citing people familiar with the matter. The slated meeting, between CVS and hedge fund Glenview Capital Management, comes amid signs investors are turning restless with a company that remains among the best-recognized in the healthcare industry but has seen its shares tumble 24% this year to date, the authors write.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- Sanders: Novo won’t be penalized for cutting Ozempic prices, STATNews reports
- FTC lawsuit ‘latest mischaracterization’ of PBM group, says JPMorgan
- FTC sues CVS, Cigna, UnitedHealth over insulin drug prices
- Oak Street Health to pay $60M to resolve alleged False Claims Act violations
- CVS Pharmacy units in MA offering hormonal contraceptive prescribing services
